Predictive models built on claims data fail in deployment more often than in validation — and the root cause is almost always the training dataset. A framework for pharma data scientists on dataset suitability, validation hierarchy, and synthetic data boundaries before model training begins.
Predictive modelling with real-world data promises a great deal: earlier identification of patients likely to respond to treatment, more accurate commercial forecasts, smarter allocation of clinical development resources. The promise is genuine. The gap between that promise and what most pharma teams actually deliver is also genuine — and it's almost always a data problem rather than a modelling problem.
Predictive modelling in pharma clusters around three primary applications. Each has distinct data requirements that need to be specified before data source evaluation begins — and treating them as variations on the same analytical problem is one of the most reliable ways to build a model that fails in deployment.
Patient stratification models identify which patients within a disease population are most likely to progress, respond to a specific treatment, experience adverse events, or transition to higher cost-of-care tiers. The data requirements include sufficient longitudinal depth to observe patient trajectories over the relevant follow-up horizon, complete diagnostic coding across the full comorbidity profile, and population coverage broad enough to ensure the training cohort is representative of the target population.
The most consistent failure mode: training on a dataset that over-represents high-utilisation patients — those with the most complete records — and under-represents patients who disengage from the healthcare system before reaching the outcome the model is designed to predict. The model learns to identify patients who look like high-utilisers, not patients who will actually experience the outcome. This is a dataset selection problem, not a modelling problem, and it cannot be fixed after the fact.
Treatment response prediction models estimate the probability that a given patient will respond to a specific therapeutic intervention, based on baseline characteristics, prior treatment history, and real-world outcome patterns in similar patients. These models are increasingly used to support label expansion submissions, personalised medicine programmes, and market access negotiations where payer evidence requirements include subgroup response data.
This is the use case where outcome labelling quality matters most. A model trained on a poorly validated patient cohort produces response estimates that are statistically precise but clinically meaningless. Sensitivity, specificity, and positive predictive value of the outcome algorithm set the upper bound on model performance before a single training epoch begins.
Commercial forecasting models use real-world prescription data, treatment patterns, and market dynamics to project brand performance, estimate market share trajectories, and support launch planning. This is the use case where data recency matters most and longitudinal depth matters least. It is also where synthetic data augmentation has its most defensible application — scenario modelling for market conditions that haven't yet occurred can be structured as synthetic data generation problems without the clinical validity constraints that apply to treatment response prediction.
Predictive models learn the patterns in a dataset — including its biases, gaps, and systematic distortions. A dataset that produces acceptable descriptive statistics may produce a deeply flawed predictive model if its structural characteristics are not evaluated carefully before training begins.
Claims data captures billing events reliably and clinical detail poorly. For many prediction tasks, important predictive features — disease severity, functional status, laboratory values, physician assessment — are either absent or proxied through indirect indicators that introduce noise. Before committing to a claims dataset for model training, map the features your model architecture requires against what the dataset actually contains. For each absent feature, assess whether a credible proxy exists and what directional bias it introduces.
Completeness analysis requires particular care in clinical datasets because missing values rarely occur randomly. A missing laboratory value may indicate a test was not performed — a clinically meaningful signal — or a result that was not recorded, which is an administrative artefact. These two scenarios require fundamentally different imputation approaches and affect model validity differently. Standard missing data analysis that treats both scenarios identically introduces systematic errors that compromise model generalisability. Structured completeness protocols that distinguish between clinically significant missingness and administrative gaps are a prerequisite for reliable clinical ML dataset preparation.
Supervised machine learning models require labelled outcomes — patients who experienced the event of interest, correctly identified and correctly timed. In claims data, outcome labelling quality depends directly on phenotype algorithm performance. A poorly validated outcome algorithm produces training labels that are systematically wrong, and a model trained on systematically wrong labels learns to predict the algorithm's misclassification pattern rather than the clinical outcome. Validation of outcome labels against gold-standard clinical records is not optional for models intended for regulatory or market access purposes.
A dataset that meets conventional data quality standards — complete, accessible, interoperable, reusable — is not necessarily AI-ready in the sense that matters for predictive model training. AI-ready clinical datasets require additional characteristics: deep provenance tracking that enables complete lineage from original data collection through every transformation step; statistical validation of distribution characteristics that affect model performance across different patient populations; semantic consistency in how clinical concepts are coded across time periods and care settings; and pre-model explainability documentation that supports regulatory audit requirements.
Deep provenance is particularly important for programmes that will ultimately support regulatory submissions or market access negotiations. A model whose training data cannot be traced back to its original source — with every transformation documented — will not survive regulatory scrutiny regardless of its predictive performance. Building provenance documentation into the data preparation process rather than attempting to reconstruct it after the fact is substantially more reliable and less expensive.
Data leakage — the inadvertent inclusion of future information in model training features — is one of the most common and most consequential errors in predictive modelling with longitudinal healthcare data. It is also one of the most reliably undetected errors in internal validation, because a leaked model performs well on any held-out set from the same data source where the leakage is present. Every feature included in the model must be verifiably observable at the time of prediction, accounting for data latency, coding lag, and claims processing delay. A model that performs well in internal validation and dramatically worse in deployment is a data leakage problem until proven otherwise.
Insurance-based patient cohorts systematically over-represent insured, high-utilisation patients. For Pan-European applications, coding practices, treatment patterns, and healthcare utilisation vary enough across Continental European markets that a model trained on data from one market may require retraining or recalibration before deployment in another. Representativeness needs to be assessed against the deployment population explicitly, not assumed from headline coverage statistics.
Beyond geographic variation, non-randomised clinical data sources introduce selection biases that require explicit detection before model training begins. Claims-based datasets exhibit systematic biases related to insurance coverage type, healthcare access patterns, and diagnostic coding practices that vary across payer environments. A model trained without identifying these biases learns them as signal — and then reproduces them in deployment, performing well in populations that resemble the training data and poorly in those that don't.
Bias detection requires comparative analysis across demographic groups, geographic regions, and healthcare systems to identify systematic differences in data collection and patient representation. Variable quality evaluation should also examine data entry patterns that create artificial correlations — default value insertion, copy-paste errors in EHR workflows, and systematic under-coding in specific care settings are common sources of dataset-level bias that are invisible in aggregate quality statistics but material to model performance.
Internal validation — splitting the training dataset into training and test sets and evaluating performance on the held-out test set — is necessary but entirely insufficient for any model intended to support regulatory submissions, market access negotiations, or clinical decision-making.
Internal validation confirms that the model has learned genuine patterns rather than overfitting the training data. It tells you whether the model works on data from the same distribution as the training set. It tells you nothing about whether it will work on a different distribution.
Temporal validation tests the model on data from a later time period than the training set, using the same data source. Claims data is particularly susceptible to temporal instability because coding practices, treatment guidelines, and healthcare system characteristics change over time in ways the training data does not represent.
External validation tests the model on data from a different source — a different claims database, a different geographic market, or ideally a clinical dataset with outcome labels derived from chart review rather than administrative coding. External validation is the standard required for regulatory submissions and should be considered the minimum acceptable validation for market access applications.
Clinical validation confirms that model predictions correspond to actual clinical outcomes in a prospective or quasi-prospective setting. This is required for any model that will directly influence clinical decision-making.
Accuracy is not an adequate performance metric for imbalanced healthcare outcome datasets. For patient stratification and clinical decision support, the relevant measures are discrimination (AUROC), calibration (Brier score, calibration curves), and net benefit analysis (decision curve analysis). Regulators and HTA bodies increasingly expect calibration evidence alongside discrimination evidence — a model that discriminates well but is poorly calibrated assigns systematically incorrect probabilities to patients, undermining clinical utility regardless of AUROC performance.
The TRIPOD statement provides the reporting standard for prediction model development and validation studies. TRIPOD+AI extends this to machine learning models. Any model intended for regulatory submission or market access support should be developed and reported against these standards from the outset.
Training data augmentation for rare outcomes is the most analytically defensible application. When the outcome of interest is rare in the available real-world dataset, GAN-based synthetic data generation with differential privacy guarantees can augment the training set to improve model performance on the minority class without exposing individual patient records to GDPR Article 9 constraints.
Algorithm development and testing under GDPR constraints is the second clear application. Developing and testing predictive model architectures on patient-level claims data triggers Article 9 obligations across Continental European markets. Synthetic data allows algorithm development to proceed without those constraints before being trained on the real dataset under appropriate data governance frameworks.
Scenario modelling for commercial forecasting is the third application — and the one with the fewest regulatory constraints. Generating synthetic patient trajectories consistent with assumed market conditions extends the analytical reach of commercial forecasting models beyond the historical data available in the training set.
Using synthetic data as the primary training source for clinical prediction models is the risk that matters most. The synthetic generation process preserves statistical relationships present in the source claims data, but those relationships are derived from billing patterns, not clinical ground truth. Neither FDA nor EMA currently accepts synthetic data as the primary evidence base for predictive model validation in regulatory submissions.
Calibration is the specific technical failure mode to watch for. Synthetic generation processes optimise for distributional similarity, not for the precise probability relationships that calibration requires. Models intended for clinical use should not rely on synthetic data for calibration validation.
The decisions that determine whether a predictive modelling programme delivers clinical and commercial value are made at the beginning — in dataset selection, outcome labelling, feature specification, and validation framework design — not during model training or after deployment.
The most consistent sources of programme failure are the hardest to detect from inside the programme: data leakage that inflates internal validation metrics, outcome label quality assumed rather than validated, population representativeness gaps that only become visible when the model is applied in a market different from the one it was trained on. An independent review at the design stage catches these problems before they become expensive. After deployment, they don't get caught — they get written off.
For a practical dataset evaluation checklist and the full framework for outcome prediction model development with real-world data, visit https://predictivemodeling.medddical.com
